BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 29284789)

  • 1. Activating and sustaining c-Myc by depletion of miR-144/451 gene locus contributes to B-lymphomagenesis.
    Ding L; Zhang Y; Han L; Fu L; Mei X; Wang J; Itkow J; Elabid AEI; Pang L; Yu D
    Oncogene; 2018 Mar; 37(10):1293-1307. PubMed ID: 29284789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-146a modulates B-cell oncogenesis by regulating Egr1.
    Contreras JR; Palanichamy JK; Tran TM; Fernando TR; Rodriguez-Malave NI; Goswami N; Arboleda VA; Casero D; Rao DS
    Oncotarget; 2015 May; 6(13):11023-37. PubMed ID: 25906746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A microRNA-mediated regulatory loop modulates NOTCH and MYC oncogenic signals in B- and T-cell malignancies.
    Ortega M; Bhatnagar H; Lin AP; Wang L; Aster JC; Sill H; Aguiar RC
    Leukemia; 2015 Apr; 29(4):968-76. PubMed ID: 25311243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCL-W has a fundamental role in B cell survival and lymphomagenesis.
    Adams CM; Kim AS; Mitra R; Choi JK; Gong JZ; Eischen CM
    J Clin Invest; 2017 Feb; 127(2):635-650. PubMed ID: 28094768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting miR-21 with NL101 blocks c-Myc/Mxd1 loop and inhibits the growth of B cell lymphoma.
    Li S; He X; Gan Y; Zhang J; Gao F; Lin L; Qiu X; Yu T; Zhang X; Chen P; Tong J; Qian W; Xu Y
    Theranostics; 2021; 11(7):3439-3451. PubMed ID: 33537096
    [No Abstract]   [Full Text] [Related]  

  • 6. Loss of PRDM11 promotes MYC-driven lymphomagenesis.
    Fog CK; Asmar F; Côme C; Jensen KT; Johansen JV; Kheir TB; Jacobsen L; Friis C; Louw A; Rosgaard L; Øbro NF; Marquart HV; Anthonsen K; Braat AK; van Lohuizen M; Ralfkiaer E; Grønbæk K; Lund AH
    Blood; 2015 Feb; 125(8):1272-81. PubMed ID: 25499759
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Musilova K; Devan J; Cerna K; Seda V; Pavlasova G; Sharma S; Oppelt J; Pytlik R; Prochazka V; Prouzova Z; Trbusek M; Zlamalikova L; Liskova K; Kruzova L; Jarosova M; Mareckova A; Kornauth C; Simonitsch-Klupp I; Schiefer AI; Merkel O; Mocikova H; Burda P; Machova Polakova K; Kren L; Mayer J; Zent CS; Trneny M; Evans AG; Janikova A; Mraz M
    Blood; 2018 Nov; 132(22):2389-2400. PubMed ID: 30213873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The class-specific BCR tonic signal modulates lymphomagenesis in a c-myc deregulation transgenic model.
    Amin R; Marfak A; Pangault C; Oblet C; Chanut A; Tarte K; Denizot Y; Cogné M
    Oncotarget; 2014 Oct; 5(19):8995-9006. PubMed ID: 25229630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A p53 defect sensitizes various stages of B cell development to lymphomagenesis in mice carrying an IgH 3' regulatory region-driven c-myc transgene.
    Fiancette R; Rouaud P; Vincent-Fabert C; Laffleur B; Magnone V; Cogné M; Denizot Y
    J Immunol; 2011 Dec; 187(11):5772-82. PubMed ID: 22039300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR expression in MYC-negative DLBCL/BL with partial trisomy 11 is similar to classical Burkitt lymphoma and different from diffuse large B-cell lymphoma.
    Zajdel M; Rymkiewicz G; Chechlinska M; Blachnio K; Pienkowska-Grela B; Grygalewicz B; Goryca K; Cieslikowska M; Bystydzienski Z; Swoboda P; Walewski J; Siwicki JK
    Tumour Biol; 2015 Jul; 36(7):5377-88. PubMed ID: 25677902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-31 and miR-17-5p levels change during transformation of follicular lymphoma.
    Thompson MA; Edmonds MD; Liang S; McClintock-Treep S; Wang X; Li S; Eischen CM
    Hum Pathol; 2016 Apr; 50():118-26. PubMed ID: 26997445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis.
    Berg T; Thoene S; Yap D; Wee T; Schoeler N; Rosten P; Lim E; Bilenky M; Mungall AJ; Oellerich T; Lee S; Lai CK; Umlandt P; Salmi A; Chang H; Yue L; Lai D; Cheng SW; Morin RD; Hirst M; Serve H; Marra MA; Morin GB; Gascoyne RD; Aparicio SA; Humphries RK
    Blood; 2014 Jun; 123(25):3914-24. PubMed ID: 24802772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic action of the microRNA-17 polycistron and Myc in aggressive cancer development.
    Tagawa H; Karube K; Tsuzuki S; Ohshima K; Seto M
    Cancer Sci; 2007 Sep; 98(9):1482-90. PubMed ID: 17608773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the understanding of MYC-induced lymphomagenesis.
    Klapproth K; Wirth T
    Br J Haematol; 2010 May; 149(4):484-97. PubMed ID: 20346013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA biogenesis is required for Myc-induced B-cell lymphoma development and survival.
    Arrate MP; Vincent T; Odvody J; Kar R; Jones SN; Eischen CM
    Cancer Res; 2010 Jul; 70(14):6083-92. PubMed ID: 20587524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myc suppression of Nfkb2 accelerates lymphomagenesis.
    Keller U; Huber J; Nilsson JA; Fallahi M; Hall MA; Peschel C; Cleveland JL
    BMC Cancer; 2010 Jul; 10():348. PubMed ID: 20598117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA profiling in ocular adnexal lymphoma: a role for MYC and NFKB1 mediated dysregulation of microRNA expression in aggressive disease.
    Hother C; Rasmussen PK; Joshi T; Reker D; Ralfkiær U; Workman CT; Heegaard S; Ralfkiær E; Grønbæk K
    Invest Ophthalmol Vis Sci; 2013 Aug; 54(8):5169-75. PubMed ID: 23821202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression.
    Sasaki N; Kuroda J; Nagoshi H; Yamamoto M; Kobayashi S; Tsutsumi Y; Kobayashi T; Shimura Y; Matsumoto Y; Taki T; Nishida K; Horiike S; Akao Y; Taniwaki M
    Exp Hematol; 2011 Aug; 39(8):817-28.e1. PubMed ID: 21640157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone H2AX suppresses translocations in lymphomas of Eμ-c-Myc transgenic mice that contain a germline amplicon of tumor-promoting genes.
    Fusello A; Horowitz J; Yang-Iott K; Brady BL; Yin B; Rowh MA; Rappaport E; Bassing CH
    Cell Cycle; 2013 Sep; 12(17):2867-75. PubMed ID: 23966158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways.
    Meng X; Carlson NR; Dong J; Zhang Y
    Oncogene; 2015 Nov; 34(46):5709-17. PubMed ID: 25823025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.